Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group

J Dermatolog Treat. 2022 Sep;33(6):2878-2880. doi: 10.1080/09546634.2022.2079596. Epub 2022 May 26.
No abstract available

Publication types

  • Observational Study
  • Multicenter Study
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Psoriasis* / drug therapy
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • guselkumab
  • Antibodies, Monoclonal, Humanized